Here is some good news for folks who don’t like needles.
Researchers have developed a way to use smartphone images of a person’s eyelids to assess blood hemoglobin levels. The ability to perform one of the most common clinical lab tests without a blood draw could help reduce the need for in-person clinic visits, make it easier to monitor patients who are in critical condition, and improve care in low- and middle-income countries where access to testing laboratories is limited.
“Our new mobile health approach paves the way for bedside or remote testing of blood hemoglobin levels for detecting anemia, acute kidney injury and hemorrhages, or for assessing blood disorders such as sickle cell anemia.” said research team leader Young Kim from Purdue University. “The COVID-19 pandemic has greatly increased awareness of the need for expanded mobile health and telemedicine srvices.”
There is possible good news is the study of Alzheimer’s disease. Researchers from Lund University, together with the Roche pharmaceutical company, have used a method to develop a new blood marker capable of detecting whether or not a person has Alzheimer’s disease. If the method is approved for clinical use, the researchers hope eventually to see it used as a diagnostic tool in primary healthcare. This autumn, they will start a trial in primary healthcare to test the technique.
Currently, a major support in the diagnostics of Alzheimer’s disease is the identification of abnormal accumulation of the substance beta-amyloid, which can be detected either in a spinal fluid sample or through brain imaging using a PET scanner. Continue reading →
A blood test for a protein could identify people in the early stages of Alzheimer’s disease a decade or more before symptoms, such as a decline in memory and thinking, emerge, as reported in Medical News Today.
This was what an international group of scientists concluded after evaluating the simple test that used blood samples from people with a rare form of Alzheimer’s disease that they had inherited.
The team included researchers from Washington University School of Medicine in St. Louis, MO and the German Center for Neurodegenerative Diseases in Tübingen, Germany.
The test looks for changes in levels of the neurofilament light chain (NfL) protein. The protein normally resides inside brain cells, or neurons, as part of their internal skeleton.